AbCellera Biologics Inc. ABCL Excess tax benefits associated with employee equity plans
Excess tax benefits associated with employee equity plans at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s excess tax benefits associated with employee equity plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s excess tax benefits associated with employee equity plans?
- AbCellera Biologics Inc. (ABCL) reported excess tax benefits associated with employee equity plans of $4.56M in Q4 2024.
- How has AbCellera Biologics Inc.'s excess tax benefits associated with employee equity plans changed year-over-year?
- AbCellera Biologics Inc.'s excess tax benefits associated with employee equity plans increased by 6.7% year-over-year, from $4.27M to $4.56M.
- What does excess tax benefits associated with employee equity plans mean?
- This reflects the tax impact resulting from the difference between the grant-date fair value of equity-based awards and the actual tax deduction realized upon exercise or vesting. It highlights the volatility in tax expense caused by fluctuations in the company's share price. A significant benefit can reduce the overall effective tax rate during periods of high equity compensation activity.